AstraZeneca’s Immunotherapy Imjudo (tremelimumab) Wins FDA Approval for Liver Cancer

AstraZeneca’s cancer immunotherapy Imjudo (tremelimumab) has won its first ever FDA approval after several trial setbacks in other cancers. The anti-CTLA-4 monoclonal antibody was approved in combination with the company’s PD-L1 inhibitor Imfinzi for the treatment of unresectable hepatocellular carcinoma, the most common type of liver cancer. The drug combination is also the first dual immunotherapy treatment regimen in liver cancer to receive FDA approval.

Visit Xtalks for more details on this story,
https://xtalks.com/astrazeneca....s-immunotherapy-imju

#shorts #AstraZeneca #Immunotherapy #Imjudo #Immuno-Oncology-Drug

• Categoria